Inebilizumab for treating AQP4-IgG-seropositive neuromyelitis optica spectrum disorders [ID6430]
Awaiting development
Reference number: GID-TA11530
Expected publication date: TBC
Following an update from the company that market inebilizumab, the timelines for the appraisal have been revised. The appraisal is now due to begin in early July 2026. Submissions are expected to be due in September 2026.